|
⚲
|
| Keyboard |
| Sofinnova Investments Inc
✚
|
|
|---|---|
| CRD # | 160297 |
| SEC # | 801-110134 |
| CIK # | 0001631134 |
| AUM | 5,368.5 M (2026-03-27) |
| Employees | 41 (49% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 650-681-8420 |
| Address | 3000 Sand Hill Road Menlo Park, CA 94025 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/27/2026) [Brochure] |
|---|
Item 5 – Fees and Compensation
A. and C.
Funds:
Sofinnova charges each Fund an investment management fee based on the value of the Fund’s assets
under management, capital commitments or invested capital (collectively, the “Management Fees”).
The Management Fee rates of the Funds range from 1.25% to 2.50% (per annum). The Management
Fees are: (i) charged monthly or quarterly in advance; and (ii) prorated for any period that is less than
a full month or calendar quarter (as applicable). In general, the proration of Management Fees is
calculated based on the number of days remaining in the applicable period. The Management Fees
are generally deducted from each Fund account by the Funds’ administrator upon Sofinnova’s
instructions. For more detailed information and a complete description of the Management Fees paid
to Sofinnova, please refer to the Fund Documents of the relevant Fund.
Sofinnova is entitled to receive performance-based compensation from the Funds in the form of
carried interest distributions or incentive allocations, which is compensation that is based on net
profits (including net unrealized gains in respect of the Public Clients) attributable to Fund
investments. This compensation ranges from 20% to 25% of the net profits, subject to a loss
carryforward or a hurdle carryforward provision in respect of the Public Clients. Further, receipt of
performance-based compensation is subject to a hurdle in respect of certain Funds. Performance-
based compensation is allocable to Sofinnova as of the end of each year in respect of certain Funds,
and upon withdrawals or other distributions with respect to all Funds. Further, Sofinnova may cause
all or any portion of performance-based compensation to which it would otherwise be entitled to be
allocated to one or more persons or entities. For more detailed information and a complete
description of the performance-based compensation allocable to Sofinnova, please refer to the Fund
Documents of the relevant Fund.
The Management Fees and performance-based compensation are subject to waiver or reduction by
Sofinnova in its sole discretion, both voluntarily and on a negotiated basis with selected investors via
side letter or other similar arrangements. In that regard, certain Fund investors who are current or
former members, principals, employees or affiliates of Sofinnova, as well as relatives or friends of
those persons, are generally not subject to Management Fees or performance-based compensation.
Separate Accounts:
The Separate Account clients generally pay an annual investment management fee that is negotiated
on a case by case basis and, in certain cases, are lower than those paid by the Funds. Separate Account
clients are generally required to pay management fees monthly in arrears. In addition, the Firm is
entitled to a performance fee pursuant to the terms of each Investment Advisory Agreement. The
Firm may reduce, waive or calculate differently the fees with respect to any Separate Account client.
B.
Funds:
In addition to management fees and performance-based compensation, each Fund generally bears its
own expenses in accordance with its Fund Documents, including, without limitation, the expenses set
forth below:
Venture Funds
• Organization costs of the Fund and the General Partners;
• All costs and expenses incurred in the purchase, holding, sale, exchange or other
disposition of portfolio securities; including taxes applicable to the Fund on account of its
operations; fees incurred in connection with the maintenance of bank or custodian
accounts; brokerage fees; legal, audit, private placement and finder’s fees paid to persons
other than the General Partner or members of the General Partner, and other expenses
incurred in connection with the registration of the Fund’s portfolio securities under the
Securities Act of 1933 (the “Securities Act”); legal and accounting fees and expenses
incurred in connection with the purchase, sale, exchange or other disposition of securities
(whether or not such purchase, sale or exchange or other disposition is ultimately
consummated); and fees and expenses of investment advisers and independent
consultants incurred in investigating and evaluating investment opportunities;
• All fees incurred in connection with the annual audit of the Fund and the preparation of
the Fund’s annual tax return, costs of independent appraisers, legal expenses of the Fund,
premiums associated with insurance, if any; preparation and other expenses associated
with annual and other reports to the investors, costs associated with any Fund meetings;
legal fees and expenses incurred in prosecuting or defending administrative or legal
proceedings relating to the Fund; administration fees and expenses;
• Indebtedness of, or guarantees made by, the Partnership, the General Partner, the
Management Company or any of their Affiliates on behalf of the Partnership (including
any credit facility, letter of credit or similar credit support), including interest with respect
thereto, or seeking to put in place any such indebtedness or guarantee
• All liquidation costs, fees, and expenses incurred by the Fund or its General Partner.
Public Funds
• The fees and expenses of the independent directors of the Fund (if applicable);
• Fees paid to proxy and securities class action advisory firms;
... |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/27/2026) [Brochure] |
|---|
Item 7 – Types of Clients Sofinnova provides investment advisory services to Funds and the Separate Accounts. With respect to the Funds, any initial and additional subscription minimums are disclosed in the relevant Fund Documents. Minimum investment amounts have been, and may in the future be, reduced in Sofinnova’s sole discretion. Although Sofinnova does not maintain a specific minimum dollar value of assets or other conditions for opening a separately managed account, any such additional account relationship would generally involve a significant minimum account size. |
| CIK | Period |
|---|---|
| 0001631134 |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Natera Inc | 0.3 | ||
| United Therapeutics Corp | 0.1 | ||
| Bristol Myers Squibb Co | 0.1 | ||
| Jazz Pharmaceuticals Inc | 0.1 | ||
| Vera Therapeutics Inc | 0.1 | ||
| Astrazeneca PLC | 0.1 | ||
| UNUM Therapeutics Inc | 0.1 | ||
| Celcuity Inc | 0.1 | ||
| Ultragenyx Pharmaceutical Inc | 0.1 | ||
| Axsome Therapeutics Inc | 0.1 | ||
| Rapport Therapeutics Inc | 0.1 | ||
| Insmed Inc | 0.1 | ||
| Alcon Inc | 0.1 | ||
| Supernus Pharmaceuticals Inc | 0.0 | ||
| BioMarin Pharmaceutical Inc | 0.0 | ||
| Biogen IDEC Inc | 0.0 | ||
| Bioage Labs Inc | 0.0 | ||
| Rhythm Pharmaceuticals Inc | 0.0 | ||
| Arrivent Biopharma Inc | 0.0 | ||
| IDEAYA Biosciences Inc | 0.0 | ||
| Immunome Inc | 0.0 | ||
| Nektar Therapeutics | 0.0 | ||
| Immatics NV | 0.0 | ||
| Bridgebio Pharma Inc | 0.0 | ||
| Dyne Therapeutics Inc | 0.0 | ||
| Inhibrx Biosciences Inc | 0.0 | ||
| Prev | Page 1 | Next | |||
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| VC | Sofinnova Venture Partners XII LP | [2025-03-20] | 500.0 M | 20.5 M |
| Offered $550,000,000 · Filed 2025-08-15 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $49,971,939 · Duration One year or less · Commission $1,966,594 · Revenue Not Applicable | ||||
| HF | Sofinnova Bioequities Enhanced Master Fund LP | [2023-03-29] | 41.5 M | 1,194.9 M |
| Filed 2025-10-10 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Sofinnova Synergy Master Fund LP | [2022-03-30] | 4.9 M | |
| Filed 2024-10-02 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| VC | Sofinnova Venture Partners Xi LP | [2022-03-30] | 500.0 M | 308.7 M |
| Offered $500,000,000 · Filed 2023-09-11 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Commission $2,869,725 · Revenue Not Applicable | ||||
| HF | Sofinnova Bioequities Master Fund Ltd | [2017-03-03] | 363.7 M | 121.4 M |
| Filed 2025-05-09 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| VC | Sofinnova Venture Partners X LP | [2017-03-03] | 595.5 M | 259.3 M |
| Offered $650,000,000 · Filed 2016-08-23 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $54,500,000 · Duration One year or less · Revenue Not Applicable | ||||
| VC | Sofinnova Venture Partners IX LP | [2015-03-27] | 389.3 M | |
| Offered $500,000,000 · Filed 2014-07-10 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $500,000,000 · Duration One year or less · Revenue Not Applicable | ||||
| VC | 80 | [2014-03-27] | 65.3 M | 2.2 M |
| Offered $110,000,000 · Filed 2014-07-07 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $44,650,000 · Duration One year or less · Revenue Not Applicable | ||||
| VC | 194 | 2012-03-30 | 0.0 M | |
| VC | 294 | 2012-03-30 | 0.2 M | |
| View All | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 9 | 2.9 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 11 | 2.4 |
| (n) Other | 0 | 0.0 |
| Total | 20 | 5.4 |
| By Discretionary | ||
| Discretionary | 20 | 5.4 |
| Non-Discretionary | 0 | 0.0 |
| Total | 20 | 5.4 |
| By Non-United States Persons | ||
| Non-United States Persons | 3.3 | |
| United States Persons | 2.1 | |
| Total | 20 | 5.4 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| James Healy | Executive Officer | 49 | 4 | |
| Garheng Kong | Executive Officer | 60 | 3 | |
| David Kabakoff | Executive Officer | 29 | 3 | |
| Srinivas Akkaraju | Executive Officer | 28 | 3 | |
| Randy Scott | Executive Officer | 26 | 3 | |
| Michael Powell | Executive Officer | 52 | 2 | |
| Anand Mehra | Executive Officer | 20 | 2 | |
| Maha Katabi | Executive Officer | 13 | 2 | |
| Sofinnova Investments Inc | Executive Officer | 3 | 2 | |
| Tom Callaway | Executive Officer | 2 | 2 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001631134] | |
| SC 13G | [0001631134] |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed |
|---|---|---|
| Sofinnova Investments Inc | Marinus Pharmaceuticals Inc | [2024-11-14] |
| Sofinnova Investments Inc | Otonomy Inc | [2021-02-16] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 549300HVTF5RFS1C0D72 |
| Comparable Firms | State | AUM |
|---|---|---|
|
Vestal Point Capital LP
✚
|
NY | 5,469.1 M |
|
Palestra Capital Management LLC
✚
|
NY | 5,441.9 M |
|
STWD Investment Management LLC
✚
|
FL | 5,434.0 M |
|
Aquatic Capital Management LLC
✚
|
IL | 5,430.4 M |
|
Stockbridge Partners LLC
✚
|
MA | 5,411.2 M |
|
Blackstone Alternative Investment Advisors LLC
✚
|
NY | 5,391.0 M |
|
Silver Rock Financial LP
✚
|
CA | 5,381.0 M |
|
Ashoka Whiteoak Capital PTE Ltd
✚
|
5,378.8 M | |
|
Mantle Ridge LP
✚
|
NY | 5,348.8 M |
|
Polus Capital Management Limited
✚
|
5,319.4 M |